Hypertension is the leading risk factor for cardiovascular (CV) disease–related death.1,2

Under the latest guidelines, an estimated 45% of US adults are hypertensive.1,2,*

*95% confidence interval of 43.9%-46.9% and 101.9-108.8 million US adults.2

A Powerful ARB

EDARBI has the power to help reduce systolic blood pressure (SBP) with statistically superior efficacy results vs Benicar® (olmesartan medoxomil) and Diovan® (valsartan).3

Abbreviation: ARB, angiotensin II
receptor blocker

Learn about EDARBI

A Powerful ARB
+ Diuretic

EDARBYCLOR has the power to help patients who need more than monotherapy to lower SBP. EDARBYCLOR displayed statistically superior blood pressure control vs Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide) in a head-to-head study.4
Learn about EDARBYCLOR

Reduce SBP,
Reduce CV Risk5,6,†

SBP treatment and control in patients with hypertension have been shown to reduce overall mortality, CV mortality, stroke, and heart failure (HF) events.5,6 Even 2 to 5 mm Hg SBP reductions may lower CV risk.6

†Study Design
SBP and mortality were analyzed in 5 large population follow-up studies: Multiple Risk Factor Intervention Trial, Whitehall Study, Chicago Western Electric Study, Framingham Heart Study, and Chicago Heart Association Detection Project in Industry. For each study, the association between initial SBP and death was examined. Follow-up lasted 6 to 19 years. Multivariate coefficients for these studies were similar and averaged.

CV RISK REDUCTION WITH EDARBI AND EDARBYCLOR HAS NOT BEEN ESTABLISHED.

Estimated reductions in CV mortality with modest lowering of SBP5,6,†,‡

‡Population estimation.

Reduce SBP,
Reduce CV Risk5,6,†

SBP treatment and control in patients with hypertension have been shown to reduce overall mortality, CV mortality, stroke, and heart failure (HF) events.5,6 Even 2 to 5 mm Hg SBP reductions may lower CV risk.6

Estimated reductions in CV mortality with modest lowering of SBP5,6,†,‡

†Study Design
SBP and mortality were analyzed in 5 large population follow-up studies: Multiple Risk Factor Intervention Trial, Whitehall Study, Chicago Western Electric Study, Framingham Heart Study, and Chicago Heart Association Detection Project in Industry. For each study, the association between initial SBP and death was examined. Follow-up lasted 6 to 19 years. Multivariate coefficients for these studies were similar and averaged.

CV RISK REDUCTION WITH EDARBI AND EDARBYCLOR HAS NOT BEEN ESTABLISHED.

‡Population estimation.
Image with three coins Image with three coins

Powerful Products Meet Powerful Savings

A comprehensive suite of savings programs is available for your patients so they can get the prescription treatment they need at a cost they can afford.
Learn more about prescription savings

FIND THE RIGHT PROGRAM FOR YOUR PATIENTS

Answer one simple question to discover which savings program is the best option for your patient.
Explore savings programs

Hear From Patients Who
Have Taken Control of Their
Blood Pressure (BP)

Access videos about patients who are successfully managing their BP with the help of EDARBI and EDARBYCLOR.
Watch patient videos

1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
2. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data. JAMA Cardiol. 2018;3(7):572-581. doi:10.1001/jamacardio.2018.1240
3. Edarbi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; [2020].
4. Edarbyclor [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; [2020].
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
6. Stamler R. Implications of the INTERSALT study. Hypertension. 1991;17(suppl 1):116-120.